These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21253747)

  • 21. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
    Desar IM; Stillebroer AB; Oosterwijk E; Leenders WP; van Herpen CM; van der Graaf WT; Boerman OC; Mulders PF; Oyen WJ
    J Nucl Med; 2010 Nov; 51(11):1707-15. PubMed ID: 20956472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms of sorafenib action in liver cancer cells.
    Cervello M; Bachvarov D; Lampiasi N; Cusimano A; Azzolina A; McCubrey JA; Montalto G
    Cell Cycle; 2012 Aug; 11(15):2843-55. PubMed ID: 22801548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
    Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
    Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF expression in cocultured retinal pigment epithelial cells.
    Du S; Wang S; Wu Q; Hu J; Li T
    Exp Eye Res; 2013 Nov; 116():151-60. PubMed ID: 24016866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.
    Hennenberg M; Trebicka J; Stark C; Kohistani AZ; Heller J; Sauerbruch T
    Br J Pharmacol; 2009 May; 157(2):258-70. PubMed ID: 19338580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration.
    Diago T; Pulido JS; Molina JR; Collett LC; Link TP; Ryan EH
    Mayo Clin Proc; 2008 Feb; 83(2):231-4. PubMed ID: 18241635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.
    Liu JY; Park SH; Morisseau C; Hwang SH; Hammock BD; Weiss RH
    Mol Cancer Ther; 2009 Aug; 8(8):2193-203. PubMed ID: 19671760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of thrombin on RPE cells are mediated by transactivation of growth factor receptors.
    Hollborn M; Petto C; Steffen A; Trettner S; Bendig A; Wiedemann P; Bringmann A; Kohen L
    Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4452-9. PubMed ID: 19369239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.
    Ramakrishnan V; Timm M; Haug JL; Kimlinger TK; Wellik LE; Witzig TE; Rajkumar SV; Adjei AA; Kumar S
    Oncogene; 2010 Feb; 29(8):1190-202. PubMed ID: 19935717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
    Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
    Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
    Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
    J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Excessive retinol intake exacerbates choroidal neovascularization through upregulated vascular endothelial growth factor in retinal pigment epithelium in mice.
    Tan X; Takahashi H; Nishida J; Aoki A; Inoue T; Yanagi Y
    Exp Eye Res; 2015 Feb; 131():77-83. PubMed ID: 25576666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
    Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoprotective effects of a blue light-filtering intraocular lens on human retinal pigment epithelium by reducing phototoxic effects on vascular endothelial growth factor-alpha, Bax, and Bcl-2 expression.
    Kernt M; Neubauer AS; Liegl R; Eibl KH; Alge CS; Lackerbauer CA; Ulbig MW; Kampik A
    J Cataract Refract Surg; 2009 Feb; 35(2):354-62. PubMed ID: 19185255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
    Xiong YQ; Sun HC; Zhang W; Zhu XD; Zhuang PY; Zhang JB; Wang L; Wu WZ; Qin LX; Tang ZY
    Clin Cancer Res; 2009 Aug; 15(15):4838-46. PubMed ID: 19638466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-throughput screening identifies compounds that protect RPE cells from physiological stressors present in AMD.
    Cai H; Gong J; Abriola L; Hoyer D; Nyscf Global Stem Cell Array Team ; Noggle S; Paull D; Del Priore LV; Fields MA
    Exp Eye Res; 2019 Aug; 185():107641. PubMed ID: 30980814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
    Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
    Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
    Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept.
    Ranjbar M; Brinkmann MP; Zapf D; Miura Y; Rudolf M; Grisanti S
    Cell Physiol Biochem; 2016; 38(2):737-47. PubMed ID: 26871551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.